Accelerate your hit identification and characterisation campaigns using Nuvisan`s highly automated laboratories, operated by experienced scientists who execute a wide range of miniaturised, cost-effective assays tailored to your therapeutic needs.
Our state-of-the art platforms support your drug discovery project by providing you with high-throughput screening (HTS) services, biochemical and cellular assays, biophysical characterizations and structural biology, helping you to make informed decisions faster.
Identifying and characterising first hits is a crucial milestone in every drug discovery project. Our custom high-throughput screening (HTS) services are designed to identify hit compounds tailored to your validated target, phenotype or mechanism. Access our library of over 3 million unique proprietary small molecule compounds for both full-deck and focused HTS screening options.
With decades of industry experience, our teams for screening, protein technologies, biophysics, structural and cell biologywork seamlessly together at every stage of the discovery process. All located within the same research facility, our teams collaborate through the entire process from designing and producing high-quality proteins to developing and interpreting tailored assays, to characterising your hits.
This close collaboration eliminates material shipping times, helps us anticipate challenges, streamlines workflows and minimises project risks, helping ensure efficient and effective outcomes. The comprehensive data package we provide supports informed decision-making to advance your drug discovery program.
Enabling robust, reproducible and meaningful results
High-quality assays are crucial for success at every stage of your drug discovery project. By automating and miniaturising experiments, HTS allows us to quickly test thousands to millions of samples for biological activity. With our unique expertise and state-of-the-art HTS equipment, we address a wide range of target classes. Our lab facilities and instrumentation enable high reproducibility and sensitivity, as well as fast turnaround times, to identify your hits efficiently.
Discover our extensive small molecule compound collection
Our industry-leading compound collection features over 3 million high-quality small molecules, derived from big pharma collections. This diverse and novel chemical space, with 80% unique structures, is unmatched by other commercial libraries. Our novel Nuvisan explorer library, focusing on lead-like compounds, streamlines the optimisation process for targeted drug discovery. With 340,000 non-proprietary compounds, it offers a cost-effective hit-finding solution.
HCA is a vital technique in drug discovery, offering valuable multiparametric insights into phenotypic changes in cells with high sensitivity. Leveraging over 15 years of experience and state-of-the-art infrastructure, we seamlessly implement HCA assays, ranging from standard 2D to complex 4D cellular assays and large-scale screening campaigns with libraries of up to 3 million proprietary small molecule compounds.
Securing high-quality protein in sufficient amounts is crucial for a successful drug discovery project. We excel in the expression and production of both soluble and membrane proteins. Our services are tailored to a variety of applications, including biophysics, biochemical assays, cell-based assays and structural biology. By partnering with us, you ensure that your drug discovery efforts are backed by reliable, high-quality protein production designed to meet your specific research needs. At every step of our production pipeline, we implement quality control measures to monitor and optimise the protein production and purification process. All purified proteins undergo an in-depth quality control regimen based on SDS-PAGE and MS, with additional biophysical and biochemical assays available.
Membrane protein platform
Our membrane protein experts specialise in purifying and characterising challenging membrane proteins, including ion channels, transporters and GPCRs. Our membrane protein platform features an efficient multistep production pipeline. In collaboration with you, we design constructs and clone genes into our in-house vector panel, utilising a range of expression systems such as baculovirus insect cells and Expi293 mammalian cells.
High-throughput small-scale expression and purification are performed under target-specific conditions, with outcomes evaluated by fluorescence size-exclusion chromatography (FSEC) and nanoDSF. These results are optimised and scaled up for large-scale purifications. Iterative and final quality controls (SDS-PAGE, SEC, nanoDSF and mass spectrometry) help ensure the production of highly pure, functional and monodisperse membrane proteins.
Enhancing drug discovery with advanced biophysical insights
Biophysical methods are crucial in the early drug discovery process. Our state-of-the-art biophysical platform can accelerate your discovery programs by providing in-depth analysis of compound–target interactions. We offer fragment screening to identify low-affinity binders in primary hit-finding campaigns and use orthogonal methods for hit validation of compounds from biochemical and cellular assays as well as screening campaigns. Our experienced biophysicists provide access to a state-of-the-art biophysics toolbox, which includes:
Key features:
Tailored mass spectrometry solutions
Mass spectrometry (MS) forms the cornerstone of advanced protein science. We offer a comprehensive range of MS technologies to meet your analytical needs. With years of expertise and a dedicated team of scientists and lab professionals, we deliver solutions designed to propel your research forward. Because every protein is unique and each challenge requires a tailored approach, we work closely with you to develop customised solutions that fit your specific requirements.
Our key offerings include:
Unlock insights with protein crystallography, cryo-EM and NMR
With over 20 years of experience using macromolecular crystallography, cryo-EM and NMR techniques, our structural biology team supports your drug discovery programs by delivering timely, high-quality 3D-structural data. Our state-of-the-art platform enables structure-based discovery for your targets of interest. We collaborate closely with your computational and medicinal chemistry design teams to maximise insights from structural data and guide the rational design of improved chemical matter, to help ensure the success of your projects.
We help you accelerate your hit-to-lead and lead optimisation campaigns by elucidating the 3D molecular binding modes of small-molecule modulators or therapeutic proteins bound to their target proteins. Our protein crystallography platform helps develop high-quality crystallisation systems, enabling timely structural information to support your optimisation programs. We have routine access to high-brilliance synchrotron sources to enable optimum conditions for high-resolution data collection.
Learn More
Our specialised protein science labs produce high-quality fresh protein samples, suitable for direct use in in-house grid preparation for cryo-EM. With regular access to high-end cryo-EM microscopes and over 16 years of cumulative industry experience, our team uses our cryo-EM platform to help ensure you receive detailed structural insights to drive your drug discovery efforts forward. Partner with us to leverage our expertise and state-of-the-art technology for your most demanding projects.
Learn More
Discover new leads with our tailored fragment screening solutions
FS is a proven method for identifying new chemical matter. We utilise biophysical and crystallographic methods to screen our proprietary library of ~2,000 fragments. Our tailored FS solutions are designed to fit your program's needs, guiding fragment growing or linking to optimise potency and selectivity. FS can also be combined with HTS for comprehensive lead-finding programs.
